Taiwan Universe BioMedicine (TaiU), a startup spun off from the National Health Research Institutes (NHRI), has completed a NT$60 million (approximately US$2 million) seed funding round led by Mosaic Seed Fund, with matching investment from the National Development Fund. The funds will accelerate development of its bivalent enterovirus vaccine and seasonal influenza VLP vaccine toward clinical trials, with plans to submit an IND application in 2026 and list on the emerging stock market in 2028.
Related articles
FinVolution Group Announces New Share Repurchase Program of Up to US$150 million
May 25, 2026
TECO Signs Acquisition Agreement with Malaysia's Dynaciate, Targeting Exponential AIDC Revenue Growth Next Year
May 25, 2026
Cyient Semiconductors Announces Strategic Financing with Edelweiss at ~ USD 500 Mn. Equity Valuation
May 25, 2026
Generated by Olivia 6